BaseLaunch funds four healthcare ventures
BaseLaunch supports carefully selected ventures in two phases. After an intense pressure test period, four projects were selected for Phase II of our second year. They now have the opportunity to further advance their breakthrough healthcare innovation and secure further investment.
The four healthcare ventures Anaveon, Pattern Biosciences, Synendos Therapeutics and a biotech in stealth mode receive funding of up to 250,000 Swiss francs as well as further support from BaseLaunch and its partners. Additionally, these projects have free-of-charge access to BaseLaunch’s co-working space and fully equipped shared laboratory in the Switzerland Innovation Park Basel Area in Allschwil.
This package allows the teams to focus on what truly matters: advancing and de-risking their science and further developing their ventures.
Applications for the BaseLaunch accelerator 2019 are now open
Further, BaseLaunch opens the next round of its accelerator program. The initiative, managed by BaselArea.swiss, is looking for people and projects with breakthrough healthcare innovations mainly in the field of therapeutics. However, applications are also open for game-changing innovation in diagnostics, medtech or related fields.
During Phase I, the selected projects develop their cases in Basel while having access to up to 10,000 Swiss francs each for consultancy and other services.
Phase II lasts at least twelve months, with each project receiving funding of up to 250,000 Swiss francs for further developing their venture.
Share this article
You might also be interested in
The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...Read More
The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...Read More
The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...Read More
The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...Read More
The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...Read More